Prasugrel for the treatment of patients with acute coronary syndrome.

Patients with clinical history of stroke or transient ischemic attack had net clinical harm: they had no evidence of clinical benefit as evaluated by primary efficacy endpoints, while exhibiting a significant trend toward major bleeding (including intracranial hemorrhage).

also in 9,775 other papers